CommonHealth Units Awarded Direct-To-Consumer and Public Relations Campaigns for Myriad Genetics.

Business Editors

PARSIPPANY, N.J.--(BUSINESS WIRE)--April 4, 2002

The Quantum Group to Develop Direct-To-Consumer Campaigns;

Shire Hall to Manage Domestic Public Relations Programs

CommonHealth today announced that two of its companies have been awarded assignments for Myriad Genetics, Inc. The Quantum Group, CommonHealth's direct-to-consumer (DTC) advertising and promotion unit, will develop the first comprehensive DTC campaign for genetic cancer testing touting the benefits of Myriad's BRACAnalysis(R) test.

Shire Hall, CommonHealth's full-service public relations firm, will oversee all domestic public relations and media relations.

CommonHealth (www.commonhealth.com), the world's leading healthcare-communications network, is a WPP Group (LSE: WPPL.L; NASDAQ/ADR: WPPGY; www.wpp.com) company.

Quantum and Shire Hall will work concurrently on their respective campaigns for the BRACAnalysis(R) test, developed to detect inherited gene mutations that are responsible for approximately 7 percent to 10 percent of all breast and ovarian cancers in women. "This is an area of high importance for women who have seen cancer prematurely take the lives of their family members, requiring a sensitive and responsible communications program," said Stu Klein, executive vice president, general manager of The Quantum Group. "We are extremely honored that Myriad has selected us to partner with them in their efforts to provide individuals carrying a BRCA mutation with the earliest possible knowledge, thereby allowing them to manage their risk more effectively," concluded Mr. Klein.

Bill Rusconi, vice president, marketing at Myriad, continued, "The combination of The Quantum Group and Shire Hall provides us with a depth of knowledge in healthcare marketing that will be required to effectively communicate the benefits of BRACAnalysis(R) testing in a responsible, motivational manner."

Myriad Genetics, Inc., is a biopharmaceutical company focused on the development of therapeutic and diagnostic products using genomic and proteomic technologies. The company has two wholly owned subsidiaries, Myriad Pharmaceuticals, Inc., and Myriad Genetic Laboratories, Inc.

Myriad Pharmaceuticals develops and markets therapeutic compounds, while its sister unit, Myriad Genetic Labs, develops and markets proprietary molecular diagnostic services. The latter also has introduced products in the fields of predictive medicine and personalized medicine. Myriad, the parent company, has formed strategic alliances with Abbott, Bayer, DuPont, Eli Lilly, Novartis, Oracle, Pharmacia, Roche, Schering AG and Schering-Plough.

CommonHealth comprises The Quantum Group, Shire Hall, Thomas Ferguson Associates, Adient, Noesis Healthcare Interactions, The Xchange Group, Health Learning Systems, ProCom International, The Conectics Group, MBS/Vox, Enterprise IG Health, EinsonHealth, MD&A/Salud, CommonHealth Europe, CommonHealth Australia and CommonHealth Kyowa.

CommonHealth also has partnerships with the following companies: Ogilvy Healthcare Network, CIA Medianetwork, Medical Broadcasting Company (MBC), Pedagogue Solutions, PDI and SoftWatch.